Relmada Therapeutics, Inc. (RLMD)
3.26
-0.02
(-0.61%)
USD |
NASDAQ |
Oct 07, 16:00
3.26
0.00 (0.00%)
After-Hours: 20:00
Relmada Therapeutics EPS Diluted (Quarterly) : -0.1149 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1149 |
| March 31, 2026 | -0.22 |
| December 31, 2025 | -0.2911 |
| September 30, 2025 | -0.304 |
| June 30, 2025 | -0.2973 |
| March 31, 2025 | -0.5774 |
| December 31, 2024 | -0.6183 |
| September 30, 2024 | -0.72 |
| June 30, 2024 | -0.5888 |
| March 31, 2024 | -0.7244 |
| December 31, 2023 | -0.8361 |
| September 30, 2023 | -0.731 |
| June 30, 2023 | -0.8406 |
| March 31, 2023 | -0.8745 |
| December 31, 2022 | -1.261 |
| September 30, 2022 | -1.311 |
| June 30, 2022 | -1.334 |
| March 31, 2022 | -1.400 |
| December 31, 2021 | -1.802 |
| September 30, 2021 | -2.438 |
| June 30, 2021 | -1.557 |
| March 31, 2021 | -1.340 |
| December 31, 2020 | -1.28 |
| September 30, 2020 | -1.054 |
| June 30, 2020 | -0.7256 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.7242 |
| June 30, 2019 | -0.4231 |
| March 31, 2019 | -0.3577 |
| December 31, 2018 | -1.115 |
| September 30, 2018 | -1.077 |
| June 30, 2018 | -1.068 |
| March 31, 2018 | -1.04 |
| December 31, 2017 | -0.44 |
| September 30, 2017 | -0.32 |
| June 30, 2017 | -0.52 |
| March 31, 2017 | -0.64 |
| December 31, 2016 | -0.36 |
| September 30, 2016 | -0.56 |
| June 30, 2016 | -1.103 |
| March 31, 2016 | -0.60 |
| December 31, 2015 | -0.88 |
| September 30, 2015 | 1.44 |
| June 30, 2015 | 2.242 |
| March 31, 2015 | -1.00 |
| December 31, 2014 | 1.60 |
| September 30, 2014 | -14.60 |
| February 28, 2014 | -0.0022 |
| September 30, 2013 | -0.497 |
| August 31, 2013 | -0.0086 |
| May 31, 2013 | -0.0166 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -12.91M |
| Total Expenses (Quarterly) | 12.91M |
| Enterprise Value | 132.15M |
| Earnings Yield | -28.53% |
| Normalized Earnings Yield | -28.47 |